MetaStat is selling for under 6.0E-4 as of the 16th of January 2026; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 6.0E-4. MetaStat has a very high chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. The performance scores are derived for the period starting the 21st of January 2025 and ending today, the 16th of January 2026. Click here to learn more.
MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The companys therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. The company has 5.88 M outstanding shares. More on MetaStat
MetaStat [MTST] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Nano-Cap' category with a current market capitalization of 205. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate MetaStat's market, we take the total number of its shares issued and multiply it by MetaStat's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. MetaStat conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 5.88 M outstanding shares.
MetaStat currently holds about 316.93 K in cash with (2.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check MetaStat Probability Of BankruptcyOwnership AllocationRoughly 98.44 % of MetaStat outstanding shares are held by general public with 1.56 pct. owned by insiders and only 0.0 % by institutional investors.
Check MetaStat Ownership Details
Our tools can tell you how much better you can do entering a position in MetaStat without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Sign In To Macroaxis Now
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
When running MetaStat's price analysis, check to measure MetaStat's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MetaStat is operating at the current time. Most of MetaStat's value examination focuses on studying past and present price action to predict the probability of MetaStat's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MetaStat's price. Additionally, you may evaluate how the addition of MetaStat to your portfolios can decrease your overall portfolio volatility.